These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37279819)

  • 21. Reduced neuronal injury after treatment with NG-nitro-L-arginine methyl ester (L-NAME) or 2-sulfo-phenyl-N-tert-butyl nitrone (S-PBN) following experimental brain contusion.
    Gahm C; Danilov A; Holmin S; Wiklund PN; Brundin L; Mathiesen T
    Neurosurgery; 2005 Dec; 57(6):1272-81; discussion 1272-81. PubMed ID: 16331176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the effects of L-NAME, 7-NI and L-NIL on carrageenan-induced hindpaw oedema and NOS activity.
    Handy RL; Moore PK
    Br J Pharmacol; 1998 Mar; 123(6):1119-26. PubMed ID: 9559895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide.
    Higuchi F; Fink AL; Kiyokawa J; Miller JJ; Koerner MVA; Cahill DP; Wakimoto H
    Mol Cancer Ther; 2018 Dec; 17(12):2551-2563. PubMed ID: 30217967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of nitric oxide synthase inhibitors on systemic hypotension, cytokines and inducible nitric oxide synthase expression and lung injury following endotoxin administration in rats.
    Wang D; Wei J; Hsu K; Jau J; Lieu MW; Chao TJ; Chen HI
    J Biomed Sci; 1999 Jan; 6(1):28-35. PubMed ID: 9933740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
    Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC
    BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of selective and non-selective inhibitors of nitric oxide synthase on morphine- and endomorphin-1-induced analgesia in acute and neuropathic pain in rats.
    Makuch W; Mika J; Rojewska E; Zychowska M; Przewlocka B
    Neuropharmacology; 2013 Dec; 75():445-57. PubMed ID: 24035921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of chronic nitric oxide synthase suppression on glioma pathophysiology.
    Swaroop GR; Kelly PA; Bell HS; Shinoda J; Yamaguchi S; Whittle IR
    Br J Neurosurg; 2000 Dec; 14(6):543-8. PubMed ID: 11272032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas.
    Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC
    PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
    Canella A; Welker AM; Yoo JY; Xu J; Abas FS; Kesanakurti D; Nagarajan P; Beattie CE; Sulman EP; Liu J; Gumin J; Lang FF; Gurcan MN; Kaur B; Sampath D; Puduvalli VK
    Clin Cancer Res; 2017 Oct; 23(20):6215-6226. PubMed ID: 28679777
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Jang JD; Jeun SS
    Stem Cells Transl Med; 2014 Feb; 3(2):172-82. PubMed ID: 24436439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inducible nitric oxide synthase inhibition improves intestinal microcirculatory oxygenation and CO2 balance during endotoxemia in pigs.
    Siegemund M; van Bommel J; Schwarte LA; Studer W; Girard T; Marsch S; Radermacher P; Ince C
    Intensive Care Med; 2005 Jul; 31(7):985-92. PubMed ID: 15959764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
    López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
    Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.